Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Kezar Life Sciences Inc. KZR

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.


Recent & Breaking News (NDAQ:KZR)

Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Business Wire 5 days ago

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire 13 days ago

Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

Business Wire July 11, 2022

Kezar Life Sciences to Present at the William Blair Biotech Focus Conference

Business Wire July 7, 2022

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire July 6, 2022

Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

Business Wire June 27, 2022

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire June 3, 2022

Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

Business Wire May 12, 2022

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire May 5, 2022

Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis

Business Wire May 3, 2022

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire April 15, 2022

Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Business Wire March 17, 2022

Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference

Business Wire March 2, 2022

Kezar Appoints Courtney Wallace to its Board of Directors

Business Wire December 10, 2021

Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis

Business Wire November 15, 2021

Kezar Life Sciences to Present at the Jefferies London Healthcare Conference

Business Wire November 11, 2021

Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.

Business Wire November 10, 2021

Kezar Reports Third Quarter Financial Results and Provides Business Update

Business Wire November 9, 2021

Kezar to Host Virtual Investor and Analyst Day on November 15, 2021

Business Wire November 3, 2021

Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies

Business Wire October 27, 2021